First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants

Jul 08 13:07 2019 Print This Article

Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.

The post First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants appeared first on DrugPatentWatch - Make Better Decisions.The post First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants appeared first on Biotechblog.

Read More

About Article Author

Biotech Blog

  Categories:

Related Items

Columbia Care is deeply undervalued: Beacon Securities

US cannabis play Columbia Care (Columbia Care Stock Quote, Chart, News NEO:CCHW) gets a positive review from Beacon Securities analyst Russell Stanley on its announcement of a collaboration with a UK pharmaceutical manufacturer for the import of Columbia’s proprietary BeneCeed CBD tablet. In an u ...

Caisse investing in Mexican pharmaceutical company

The Caisse de dépôt et placement du Québec is investing US$500 million in Laboratorios Sanfer, an independent Mexican pharmaceutical company. The company, which currently maintains a ... ...

Tech Talk for Tuesday August 20th 2019

  StockTwits released yesterday @EquityClock Vertex Pharmaceutical $VRTX, a NASDAQ 100 stock moved above $186.33 setting an intermediate uptrend. Dollarama $DOL.CA, a TSX 60 stock moved above $50.74 extending an intermediate uptrend.   Trader’s Corner   Equity Indices and related ETFs Daily ...

Opportunities for Generic Drug Development

Amid public outcry over rising costs of brand-name drugs, the prices of generic medicines have been falling, raising fears about the sustainability and profitability of major generics companies. But some… The post Opportunities for Generic Drug Development appeared first on DrugPatentWatch - Make ...

Week Ahead: With Nifty Vulnerable At Higher Levels, These Sectors May Act As Safe Havens

With a 3-day working week, the markets moved along expected lines and stayed within a limited range. As anticipated, the NIFTY did not make any directional move, remaining within the 50-Week MA and 100-Week MA (as mentioned in our previous weekly note). After flirting with the 50-Week MA, which sta ...

Week Ahead: Range-Bound Move Expected In The Truncated Week; These Sectors May Relatively Outperform

After bouncing off its 100-Week MA in the previous week, the markets attempted to take a breather and stabilize during the past week. The NIFTY was able to bounce back once again from the 100-Week MA; this pullback was aided by the oversold nature of the markets on the short-term charts. After an i ...

NAFTA 2.0 Update

There have been a few developments in the NAFTA 2.0/USMCA/CUSMA process in the past few weeks. 1. The Government of Mexico published in the July 29, 2019 issued of the Official Gazette a decree that was signed by Mexican President Andrés Manuel López Obrador to complete the final step in the rati ...

Echelon lowers price target on Cipher Pharma, maintains “Buy” rating

With the stock on a multi-year decline and the board looking at its “strategic options”, Echelon Wealth Partners analyst Doug Loe has lowered his price target on Cipher Pharmaceuticals (Cipher Pharmaceuticals News, Stock Quote, Chart TSX:CPH). Yesterday, Cipher announced that Criag Mull had bee ...

Tech Talk for Tuesday July 30th 2019

Pre-opening Comments for Tuesday July 30th U.S. equity index futures moved lower this morning. S&P 500 futures were down 12 points in pre-opening trade. Index futures were virtually unchanged following release of economic news at 8:30 AM EDT. Consensus for June Personal Spending was an increase of ...

Canada and the EU Agree to WTO Dispute Settlement Work-Around

On July 25, 2019, Canada and the European Union issued a joint statement confirming they had reached an Interim Appeal Arbitration Arrangement to resolve World Trade Organization (“WTO”) disputes (at the Appellate Body stage). Starting on December 10, 2019, the Appellate Body will be unable to ...